Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Veracyte, Inc.

< Previous 1 2 3 4 5 Next >
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces First Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Release of Inaugural ESG Report
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Third Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS